You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
《大行報告》瑞信首予賽生藥業(06600.HK)「跑贏大市」評級 目標價24元
阿思達克 04-07 15:34
瑞信發表研究報告,首予賽生藥業(06600.HK)「跑贏大市」投資評級,目標價24元。報告稱,其核心藥品日達仙(Zadaxin)去年銷售18億元人民幣。瑞信表示,其產品線渠道有七款候選藥,料未來18個月迎來催化劑,包括多項資產如RRx-001、PEN-886、Vibativ及用於治療高危神經母細胞瘤的naxitamab。

報告稱,近期賽生藥業旗下Angiomax未有入圍第四輪藥品集中採購,或對Angiomax銷售構成壓力。瑞信稱,喜好其包括Zadaxin的產品組合,可產生穩定現金流及增長。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account